NZ705813A - Treatment of mild and moderate alzheimer’s disease - Google Patents

Treatment of mild and moderate alzheimer’s disease

Info

Publication number
NZ705813A
NZ705813A NZ705813A NZ70581313A NZ705813A NZ 705813 A NZ705813 A NZ 705813A NZ 705813 A NZ705813 A NZ 705813A NZ 70581313 A NZ70581313 A NZ 70581313A NZ 705813 A NZ705813 A NZ 705813A
Authority
NZ
New Zealand
Prior art keywords
treatment
mild
disease
moderate alzheimer
phenoxy
Prior art date
Application number
NZ705813A
Other languages
English (en)
Inventor
Lopez Maria Carmen Valcarce
Cesare Orlandi
David J Clark
Imogene M Grimes
Matthew J Kostura
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Priority to NZ739521A priority Critical patent/NZ739521A/en
Publication of NZ705813A publication Critical patent/NZ705813A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
NZ705813A 2012-10-05 2013-10-02 Treatment of mild and moderate alzheimer’s disease NZ705813A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ739521A NZ739521A (en) 2012-10-05 2013-10-02 Pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261710229P 2012-10-05 2012-10-05
PCT/US2013/062964 WO2014055588A1 (en) 2012-10-05 2013-10-02 Treatment of mild and moderate alzheimer's disease

Publications (1)

Publication Number Publication Date
NZ705813A true NZ705813A (en) 2018-02-23

Family

ID=49354960

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ705813A NZ705813A (en) 2012-10-05 2013-10-02 Treatment of mild and moderate alzheimer’s disease
NZ739521A NZ739521A (en) 2012-10-05 2013-10-02 Pharmaceutical compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ739521A NZ739521A (en) 2012-10-05 2013-10-02 Pharmaceutical compositions

Country Status (15)

Country Link
EP (1) EP2903606A1 (https=)
JP (2) JP6566868B2 (https=)
KR (1) KR20150064743A (https=)
CN (2) CN104703592A (https=)
AU (2) AU2013327450B2 (https=)
BR (1) BR112015007641A8 (https=)
CA (1) CA2886785C (https=)
EA (1) EA201590687A1 (https=)
HK (1) HK1207004A1 (https=)
IL (1) IL237730B (https=)
IN (1) IN2015DN03734A (https=)
MX (1) MX377733B (https=)
NZ (2) NZ705813A (https=)
SG (2) SG11201502210VA (https=)
WO (1) WO2014055588A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー [3-(4-{2-ブチル-1-[4-(4-クロロ-フェノキシ)-フェニル]-1h-イミダゾール-4-イル}-フェノキシ)-プロピル]-ジエチル-アミンの代謝産物
WO2020086388A1 (en) * 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CN114031687B (zh) * 2021-11-12 2022-06-07 深圳市人民医院 靶向rage的纳米抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4481011B2 (ja) * 2002-03-05 2010-06-16 トランス テック ファーマ,インコーポレイテッド リガンドのrageとの相互作用を阻害する単環式および二環式アゾール誘導体
EP1635823A1 (en) * 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ,インコーポレイテッド [3−(4−{2−ブチル−1−[4−(4−クロロ−フェノキシ)−フェニル]−1h−イミダゾール−4−イル}−フェノキシ)−プロピル]−ジエチルアミンの結晶形態
CN101663280A (zh) * 2007-04-05 2010-03-03 转化技术制药公司 [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
US8933040B2 (en) * 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
HK1207004A1 (zh) 2016-01-22
AU2013327450A1 (en) 2015-05-14
CN104703592A (zh) 2015-06-10
JP2019163301A (ja) 2019-09-26
EP2903606A1 (en) 2015-08-12
AU2018203434A1 (en) 2018-06-07
KR20150064743A (ko) 2015-06-11
IN2015DN03734A (https=) 2015-09-18
NZ739521A (en) 2019-06-28
CA2886785A1 (en) 2014-04-10
JP6894940B2 (ja) 2021-06-30
CN110292638A (zh) 2019-10-01
BR112015007641A2 (pt) 2017-07-04
MX377733B (es) 2025-03-11
MX2015003732A (es) 2015-09-23
BR112015007641A8 (pt) 2018-04-03
SG11201502210VA (en) 2015-04-29
EA201590687A1 (ru) 2015-09-30
JP2015535850A (ja) 2015-12-17
IL237730B (en) 2018-10-31
SG10201702648YA (en) 2017-04-27
CA2886785C (en) 2022-06-07
WO2014055588A1 (en) 2014-04-10
AU2013327450B2 (en) 2018-07-12
JP6566868B2 (ja) 2019-08-28

Similar Documents

Publication Publication Date Title
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
PH12016501439B1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201590735A1 (ru) 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
IN2015DN01119A (https=)
NZ705813A (en) Treatment of mild and moderate alzheimer’s disease
PH12015501398A1 (en) New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
UA117154C2 (uk) Антагоністи s1p3
MD4780B1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
NZ727251A (en) Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s
TN2011000262A1 (en) Hemifumarate salt of 1-[4-(cyclohexyl-3-trifluoromethyl-benzyloxymino)-ethyl]-2-ethyl-benzyl]-a zetidine-3-carboxylic acid

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3600053, VTV THERAPEUTICS LLC, 4170 MENDEHALL OAKS PARKWAY HIGHWAY POINT, NORTH CAROLINA 27265, US

Effective date: 20180110

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2019 BY CPA GLOBAL

Effective date: 20180830

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2020 BY CPA GLOBAL

Effective date: 20190829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2021 BY CPA GLOBAL

Effective date: 20200820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2022 BY CPA GLOBAL

Effective date: 20210819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2023 BY COMPUTER PACKAGES INC

Effective date: 20220917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2024 BY COMPUTER PACKAGES INC

Effective date: 20230930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2025 BY COMPUTER PACKAGES INC

Effective date: 20240917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2026 BY COMPUTER PACKAGES INC

Effective date: 20250917